Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Annovis Bio, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MALVERN, PA., AUG. 12, 2025 (GLOBE NEWSWIRE) -- ANNOVIS BIO, INC. (NYSE: ANVS) ("ANNOVIS" OR THE COMPANY), A LATE-STAGE CLINICAL DRUG PLATFORM COMPANY PIONEERING TRANSFORMATIVE THERAPIES FOR NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE (AD) AND PARKINSON'S DISEASE (PD), TODAY PROVIDED CORPORATE UPDATES AND SECOND QUARTER 2025 FINANCIAL RESULTS.

ANNOVIS PROVIDES CORPORATE UPDATES AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

ANNOVIS ACHIEVES COMPREHENSIVE INTELLECTUAL PROPERTY (IP) PROTECTION NOW COVERING BOTH THE ORIGINAL SEMI-CRYSTALLINE AND NEW CRYSTALLINE FORMS OF BUNTANETAP. BOTH FORMS ARE COVERED BY A TOTAL OF 13 PATENT FAMILIES.

ANNOVIS COMPLETES FULL PATENT TRANSFER TO CRYSTAL BUNTANETAP

MALVERN, PA., JUNE 26, 2025 (GLOBE NEWSWIRE) -- ANNOVIS BIO, INC. (NYSE: ANVS) ("ANNOVIS" OR THE COMPANY), A LATE-STAGE CLINICAL DRUG PLATFORM COMPANY PIONEERING TRANSFORMATIVE THERAPIES FOR NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE (AD) AND PARKINSON'S DISEASE (PD), TODAY ANNOUNCED ITS SENIOR MANAGEMENT WILL ATTEND THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC), TAKING PLACE JULY 2731, 2025, IN TORONTO, CANADA.

ANNOVIS TO ATTEND THE AAIC 2025 WITH FOUR POSTER PRESENTATIONS

MALVERN, PA., JUNE 19, 2025 (GLOBE NEWSWIRE) -- ANNOVIS BIO, INC. (NYSE: ANVS) ("ANNOVIS" OR THE COMPANY), A LATE-STAGE CLINICAL DRUG PLATFORM COMPANY PIONEERING TRANSFORMATIVE THERAPIES FOR NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE (AD) AND PARKINSON'S DISEASE (PD), TODAY ANNOUNCED IT RECEIVED NOTIFICATION (THE "ACCEPTANCE LETTER") FROM THE NEW YORK STOCK EXCHANGE ("NYSE") THAT THE NYSE HAS ACCEPTED THE COMPANY'S PREVIOUSLY-SUBMITTED PLAN (THE "PLAN") TO REGAIN COMPLIANCE WITH THE NYSE'S CONTINUED LISTING STANDARDS RELATING TO MINIMUM MARKET CAPITALIZATION AND STOCKHOLDERS' EQUITY.

ANNOVIS ANNOUNCES NYSE ACCEPTANCE OF PLAN TO REGAIN LISTING COMPLIANCE

MALVERN, PA., JUNE 05, 2025 (GLOBE NEWSWIRE) -- ANNOVIS BIO, INC. (NYSE: ANVS) ("ANNOVIS" OR THE "COMPANY"), A CLINICAL-STAGE DRUG PLATFORM COMPANY DEVELOPING NOVEL THERAPIES FOR NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE (AD) AND PARKINSON'S DISEASE (PD), TODAY ANNOUNCED IT WILL HOST A LIVE WEBCAST WHERE MARIA MACCECCHINI, PH.D., PRESIDENT AND CEO, WILL PROVIDE UPDATES AND ANSWER QUESTIONS FROM THE AUDIENCE.

ANNOVIS TO HOST WEBINAR AND LIVE Q&A ON JUNE 24, 2025

MALVERN, PA., MAY 13, 2025 (GLOBE NEWSWIRE) -- ANNOVIS BIO INC. (NYSE: ANVS) ("ANNOVIS" OR THE COMPANY), A LATE-STAGE CLINICAL DRUG PLATFORM COMPANY PIONEERING TRANSFORMATIVE THERAPIES FOR NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE (AD) AND PARKINSON'S DISEASE (PD), TODAY PROVIDED CORPORATE UPDATES AND FIRST QUARTER 2025 FINANCIAL RESULTS.

ANNOVIS PROVIDES CORPORATE UPDATES AND REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

MALVERN, PA., APRIL 29, 2025 (GLOBE NEWSWIRE) -- ANNOVIS BIO INC. (NYSE: ANVS) ("ANNOVIS" OR THE "COMPANY"), A LATE-STAGE CLINICAL DRUG PLATFORM COMPANY DEVELOPING TRANSFORMATIVE THERAPIES FOR NEURODEGENERATIVE DISORDERS SUCH AS ALZHEIMER'S DISEASE (AD) AND PARKINSON'S DISEASE (PD), TODAY ANNOUNCED THE APPOINTMENT HUI LIU AS DIRECTOR OF BIOSTATISTICS.

ANNOVIS BIO APPOINTS HUI LIU AS DIRECTOR OF BIOSTATISTICS

MALVERN, PA., MARCH 27, 2025 (GLOBE NEWSWIRE) -- ANNOVIS BIO, INC. (NYSE: ANVS) (ANNOVIS OR THE COMPANY), A LATE-STAGE CLINICAL DRUG PLATFORM COMPANY PIONEERING TRANSFORMATIVE THERAPIES FOR NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE (AD) AND PARKINSON'S DISEASE (PD), TODAY ANNOUNCED THAT ON MARCH 26, 2025, IT RECEIVED NOTICE (THE NOTICE) FROM THE NEW YORK STOCK EXCHANGE (NYSE) THAT IT IS NO LONGER IN COMPLIANCE WITH THE NYSE CONTINUED LISTING STANDARDS SET FORTH IN SECTION 802.01B OF THE NYSE'S LISTED COMPANY MANUAL DUE TO THE FACT THAT THE COMPANY'S AVERAGE GLOBAL MARKET CAPITALIZATION OVER A CONSECUTIVE 30 TRADING-DAY PERIOD WAS LESS THAN $50 MILLION WHILE ITS STOCKHOLDERS' EQUITY WAS LESS THAN $50 MILLION.

ANNOVIS BIO, INC. RECEIVES CONTINUED LISTING STANDARD NOTICE FROM THE NYSE

MALVERN, PA., MARCH 25, 2025 (GLOBE NEWSWIRE) -- ANNOVIS BIO INC. (NYSE: ANVS) ("ANNOVIS"), A LATE-STAGE CLINICAL DRUG PLATFORM COMPANY PIONEERING TRANSFORMATIVE THERAPIES FOR NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE (AD) AND PARKINSON'S DISEASE (PD), TODAY ANNOUNCED ITS PARTICIPATION IN THE AD/PD 2025 TAKING PLACE APRIL 1-5 IN VIENNA.

ANNOVIS TO ATTEND AD/PD2025 WITH EXTENSIVE SCIENTIFIC PROGRAM

MALVERN, PA., MARCH 21, 2025 (GLOBE NEWSWIRE) -- ANNOVIS BIO INC. (NYSE: ANVS) ("ANNOVIS" OR THE COMPANY), A LATE-STAGE CLINICAL DRUG PLATFORM COMPANY PIONEERING TRANSFORMATIVE THERAPIES FOR NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE (AD) AND PARKINSON'S DISEASE (PD), TODAY PROVIDED CORPORATE UPDATES AND FOURTH QUARTER/FULL YEAR 2024 FINANCIAL RESULTS.

Annovis Bio, Inc.

ANVS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Annovis Bio, Inc.

ANVS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ANVS